Jazz Pharmaceuticals plc Fair Value Disclosure
| December 31, 2025 | December 31, 2024 | ||||||||||||||||||||||||||||||||||
| Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Total Estimated Fair Value | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Total Estimated Fair Value | ||||||||||||||||||||||||||||||
| Assets: | |||||||||||||||||||||||||||||||||||
| Available-for-sale securities: | |||||||||||||||||||||||||||||||||||
| Money market funds | $ | 629,153 | $ | — | $ | 629,153 | $ | 1,253,970 | $ | — | $ | 1,253,970 | |||||||||||||||||||||||
| Time deposits | — | 1,130,000 | 1,130,000 | — | 790,000 | 790,000 | |||||||||||||||||||||||||||||
| Foreign exchange forward contracts | — | 6,259 | 6,259 | — | 2,250 | 2,250 | |||||||||||||||||||||||||||||
| Interest rate contracts | — | — | — | — | 991 | 991 | |||||||||||||||||||||||||||||
| Totals | $ | 629,153 | $ | 1,136,259 | $ | 1,765,412 | $ | 1,253,970 | $ | 793,241 | $ | 2,047,211 | |||||||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||||||||||||||
| Foreign exchange forward contracts | $ | — | $ | 3,760 | $ | 3,760 | $ | — | $ | 10,198 | $ | 10,198 | |||||||||||||||||||||||
| Interest rate contracts | — | 465 | 465 | — | — | — | |||||||||||||||||||||||||||||
| Totals | $ | — | $ | 4,225 | $ | 4,225 | $ | — | $ | 10,198 | $ | 10,198 | |||||||||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 26, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Mar 1, 2023 | |
| 2021 | Mar 1, 2022 | |
| 2020 | Feb 23, 2021 | |
| 2019 | Feb 25, 2020 | |
| 2018 | Feb 26, 2019 | |
| 2017 | Feb 27, 2018 | |
| 2016 | Feb 28, 2017 | |
| 2015 | Feb 23, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.